March 20, 2025
6:55 am
—
8:10 am
Non-CME/CE Bonus Presentation
Treating MDD: A Rapid-Acting Oral Antidepressant with Multimodal Activity
Sponsored by Axsome Therapeutics
Speaker: Gustavo Alva, MD, DFAPA
This branded symposium will highlight the current unmet needs in MDD and present a treatment option with rapid symptom improvement for adult patients with MDD.
March 20, 2025
12:50 pm
—
2:05 pm
Non-CME/CE Bonus Presentation
Tardive Dyskinesia Is Personal: Go Beyond the Data With a Real Patient Story
Sponsored by Neurocrine Biosciences
Speaker: Charles Nguyen, MD, DFAPA & Patient Ambassador
This program will communicate the burden and impacts of tardive dyskinesia; review a patient’s experience with tardive dyskinesia and the impact it has had on their mental and physical well-being; and discuss an FDA-approved treatment for adults with tardive dyskinesia, with detailed pharmacology discussion.
March 20, 2025
4:50 pm
—
5:50 pm
Non-CME/CE Bonus Presentation
Learn About COBENFY (xanomeline and trospium chloride): Where Does It Fit in Your Practice?
Sponsored by Bristol Myers Squibb
Speaker: Robert Morton, MD
Don't miss this opportunity to learn about COBENFY as a treatment option for your patients. Explore COBENFY's clinical profile, including efficacy, safety, and dosing information. This program also highlights practical considerations when prescribing COBENFY.
March 21, 2025
7:00 am
—
8:00 am
Non-CME/CE Bonus Presentation
Insights on Assessing the Severity and Impact of Tardive Dyskinesia (TD)
Sponsored by Teva Pharmaceuticals
Speaker: Jennifer Sampang, PhD, PMHNP-BC, APRN, MSN
This presentation offers a comprehensive review of TD, covering impact, screening, assessment, diagnosis, and appropriate treatment. Through videos of actual patients, audiences can learn about the impact of TD and hone their ability to identify, assess, and accurately diagnose TD movements. Considerations for appropriate treatment, including the role of AUSTEDO XR, are also discussed.
March 21, 2025
12:40 pm
—
1:40 pm
Non-CME/CE Bonus Presentation
Rethinking Maintenance Treatment of Bipolar I Disorder: An Expert Discusses Therapeutic Options for Your Adult Patients
Sponsored by Otsuka America Pharmaceutical, Inc. and Lundbeck
Speaker: Craig Chepke, MD, DFAPA
Explore the value of long-acting injectables (LAIs) in managing bipolar I disorder through the lens of a hypothetical patient case.
March 21, 2025
2:50 pm
—
3:50 pm
Non-CME/CE Bonus Presentation
The Evolution of Specifiers and a Treatment Option for BOTH Bipolar I and Bipolar II Depression in Adults
Sponsored by Intra-Cellular Therapies
Speaker: Joseph F. Goldberg, MD
Diagnostic specifiers have evolved to better categorize the experience of patients with bipolar disorder. This presentation offers insight into specifiers and reviews a treatment option approved for BOTH bipolar I and bipolar II depression in adults.
March 21, 2025
5:25 pm
—
6:25 pm
Non-CME/CE Bonus Presentation
Expanding & Empowering Treatment Choice with SPRAVATO® Alone or in Combination with an Oral AD
Sponsored by Johnson & Johnson Innovative Medicine
Speakers: Mitchell Glaser, MD & Chet Robachinski, MD
March 22, 2025
6:55 am
—
7:55 am
Non-CME/CE Bonus Presentation
Schizophrenia Pathophysiology and Treatment Strategies
Sponsored by Bristol Myers Squibb
Speaker: Leslie Citrome, MD, MPH
Managing schizophrenia presents numerous challenges, including the need to address various symptom domains. This presentation will explore ongoing research and data-driven trends in adjunctive treatment approaches and examine the underlying pathophysiology across neurotransmitter systems that may contribute to the symptoms of schizophrenia.
March 22, 2025
12:40 pm
—
1:40 pm
Non-CME/CE Bonus Presentation
UZEDY: Discover the Features of a Different Kind of LAI
Sponsored by Teva Pharmaceuticals
Speaker: Leslie Citrome, MD, MPH
This presentation reviews the importance of relapse prevention and explores the possible role of LAIs, such as UZEDY, in patients with schizophrenia.
March 20, 2025
9:25 am
—
10:25 am
CME/CE Bonus Presentation
Exploring Long-Acting Injectable Antipsychotics: Expert Insights and Patient Perspectives on the Schizophrenia Treatment Journey
Supported by an independent educational grant from Janssen Pharmaceuticals Inc., administered by Janssen Scientific Affairs, LLC
Additional 1.0 CME Credits™
Christoph U. Correll, MD; Alan F. Breier, MD; Desiree M. Matthews, PMHNP-BC; Bethany Yeiser - PATIENT ADVOCATE
Long-acting injectable (LAI) antipsychotic medications are an effective option for managing positive symptoms associated with schizophrenia. But how do they fit into an overall treatment plan? Which patients would benefit from switching to LAI medications? And how should clinicians engage patients in shared decision-making about LAI medications? In this live panel discussion, clinician experts will talk with a patient about her treatment journey, with a focus on LAI medications, how best to talk with patients about them, and the potential impact of these medications on patient quality of life.
March 21, 2025
9:10 am
—
10:10 am
CME/CE Bonus Presentation
Advances in Depression Care: Enhancing Quality of Life with Rapid-Acting Therapeutics
Supported by an independent educational grant from Axsome Therapeutics, Inc.
Additional 1.0 CME Credits™
Leslie Citrome, MD, MPH; Brooke A. Kempf, PMHNP; Sagar V. Parikh, MD, FRCPC
Join us for a symposium on major depressive disorder (MDD) designed to encourage the exchange of ideas between leaders in the field and attendees. In this live session, 3 faculty and 2 patients will illuminate their different treatment journeys. Faculty will interview patients about their experiences, demonstrating best practices in communication, SDM, and goal setting. Presentations on data will be interspersed and include current unmet needs in treatment options for MDD; how novel therapies fit into the current treatment paradigm for MDD; pathophysiology of MDD and the role of glutamate and GABA; MOAs of novel, rapid-acting antidepressants; side effect profiles of novel, rapid-acting antidepressants compared to side effect profile of SSRIs/SNRIs; identifying patient profiles for those who would benefit from a rapid-acting antidepressant; and patient lived experience and MDD treatment journey.
March 22, 2025
10:30 am
—
11:30 am
CME/CE Bonus Presentation
Digital Updates: Innovative Technology for the Management of Negative Symptoms of Schizophrenia
Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Additional 1.0 CME Credits™
Leslie Citrome, MD, MPH; Christoph U. Correll, MD
Join us for a news report-style symposium on the emerging role of prescription digital therapeutics (PDTs) in schizophrenia care, focusing on the potential to address negative symptoms — an area of significant unmet need. This symposium is designed to foster audience participation and provide valuable insights from experts in the field who will differentiate evidence-based PDTs from wellness applications, examine clinical trial data, and discuss how to identify appropriate patients who may benefit from PDTs as part of their treatment plan. A faculty host and the expert panelists will report the latest insights of integrating PDTs into clinical practice and overcoming barriers to adoption. Don’t miss out on this interactive and informative news report program!